Biontech Se Spon Ads Each Rep 1 Ord Shs (BNTX) Stock
German biotech company developing mRNA vaccines and cancer treatments. Here's the price, business snapshot, and what's worth knowing about Biontech Se Spon Ads Each Rep 1 Ord Shs in August 2026.
BioNTech SE (BNTX) is a Germany-based biotechnology company known for its mRNA platform and as a co-developer of the Comirnaty COVID-19 vaccine with Pfizer. With a market capitalisation around $25.2 billion, BioNTech combines infectious-disease programmes with an expanding oncology pipeline that includes personalised cancer vaccines and other immunotherapies. Investors should note that the company’s recent revenues were materially bolstered by pandemic vaccine sales, which may be cyclical as public-health demand shifts. BioNTech is R&D intensive, requiring significant spending and clinical progress to unlock long-term value; regulatory approvals, trial outcomes and competition from other vaccine and cancer-therapy developers are key catalysts and risks. Strategic partnerships and manufacturing scale are strengths, but the share price can be volatile. This is general educational information, not investment advice — prospective investors should consider their risk tolerance and seek personalised advice.
Why It’s Moving
BioNTech is drawing renewed attention as analyst upside stays high and buyback support reinforces the valuation case.
- Analysts continue to see meaningful upside in BioNTech as consensus 12-month price targets cluster well above the current share price, reflecting confidence that the company’s pipeline and commercial base can support a recovery.
- Recent analyst commentary has been mixed but still constructive, with some firms trimming targets while others maintained or upgraded ratings, signaling debate over near-term execution rather than a broad bearish shift.
- The stock’s move is also being shaped by a recent $1 billion share buyback announcement, which investors often read as a signal that management views the shares as undervalued and has confidence in the company’s cash position.
BioNTech is drawing renewed attention as analyst upside stays high and buyback support reinforces the valuation case.
- Analysts continue to see meaningful upside in BioNTech as consensus 12-month price targets cluster well above the current share price, reflecting confidence that the company’s pipeline and commercial base can support a recovery.
- Recent analyst commentary has been mixed but still constructive, with some firms trimming targets while others maintained or upgraded ratings, signaling debate over near-term execution rather than a broad bearish shift.
- The stock’s move is also being shaped by a recent $1 billion share buyback announcement, which investors often read as a signal that management views the shares as undervalued and has confidence in the company’s cash position.
When is the next earnings date for BIONTECH SE SPON ADS EACH REP 1 ORD SHS (BNTX)?
BioNTech’s next earnings date is expected on November 3, 2026. The report should cover the third quarter of 2026. If the date shifts, it is typically released in early November based on the company’s historical reporting pattern.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying BioNTech's stock with a target price of $141.14, indicating significant growth potential.
Financial Health
BioNTech is generating strong revenue and cash flow, with impressive profit margins from its operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring BNTX
mRNA Vaccines: Could Non-COVID Markets Drive Growth?
The FDA has granted its first-ever approval for an mRNA seasonal flu vaccine, moving the groundbreaking technology beyond its pandemic origins. This regulatory milestone creates compelling investment opportunities across innovative biotechnology firms and the specialized supply chains that support them.
Published: 7 August 2026
Explore BasketLNP Patent Holders Shape Drug Delivery Value 2025
The massive settlement between Moderna and Arbutus/Genevant highlights the critical value of the lipid nanoparticle (LNP) technology used in mRNA vaccines. This creates a potential investment opportunity in companies that hold key patents for drug delivery systems, as they may be poised for lucrative licensing deals or acquisitions.
Published: 4 March 2026
Explore BasketBiotech Patent Dispute Explained (BioNTech vs Moderna)
BioNTech is suing Moderna for patent infringement over its next-gen COVID-19 vaccine, escalating the legal rivalry between the two biotech leaders. This dispute creates a potential opening for other vaccine developers to gain a competitive edge while the giants are locked in a legal battle.
Published: 20 February 2026
Explore BasketBeyond Vaccines: The mRNA Revolution
BioNTech's strong vaccine sales are fueling its expansion into new medical fields, particularly cancer treatment. This strategic shift highlights a broader investment opportunity in companies pioneering the next wave of mRNA-based therapies.
Published: 5 August 2025
Explore BasketHypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: 15 July 2025
Explore BasketBiotech's IP Moat
This carefully selected group of stocks features biotech companies with powerful patent portfolios. These firms are at the forefront of medical innovation in areas like gene editing and mRNA technology, where intellectual property can create lasting competitive advantages and drive long-term growth.
Published: 11 July 2025
Explore BasketBuffett's Billions: The Philanthropy Effect
Warren Buffett just donated $6 billion to major foundations like the Gates Foundation. This curated list features companies in global health, agriculture, and education that are perfectly positioned to benefit from this massive philanthropic wave.
Published: 1 July 2025
Explore BasketGerman Stocks Soaring
Discover a carefully selected collection of German companies that have been dramatically outperforming their western counterparts. Our team of professional analysts has identified these standout stocks as Germany's economy shows promising signs of growth in 2025.
Published: 15 May 2025
Explore BasketWhy You’ll Want to Watch This Stock
mRNA platform potential
The mRNA approach underpins vaccines and new therapeutics, offering scalability and adaptability, though clinical success and commercial demand can vary.
Oncology pipeline progress
BioNTech’s cancer programmes, including personalised vaccines, could be long-term value drivers if trials succeed, but outcomes and timelines are uncertain.
Partnerships and scale
Collaborations—most notably with Pfizer—boost manufacturing reach and revenue potential, though reliance on partners and market shifts present risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
